Should I Buy MTNB? MTNB 2026 Analysis

Should You Buy Matinas BioPharma Holdings Inc (MTNB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.590

1 Day change

3.15%

52 Week Range

3.090

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is below the nearest support (S1 ~0.583) and the broader trend is still bearish.
No Intellectia buy signals (AI Stock Picker / SwingMax), so there’s no strong short-term edge for an impatient entry.
With no revenue and a worsening loss profile (latest quarter), this is more speculation than a time-sensitive opportunity.
If already holding, the setup argues for reducing exposure ahead of uncertain catalysts rather than adding here.

Technical Analysis

Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5, indicating price is still in a longer-term downtrend.
Momentum: MACD histogram is positive and expanding (0.00323), suggesting a minor bullish momentum attempt, but it hasn’t flipped the moving-average trend yet.
RSI(6) ~54.4: neutral—no oversold bounce signal.
Levels: Current price 0.5716 is below S1 (0.583) and well below pivot (0.671). Next support S2 ~0.528; resistance levels at ~0.671 (pivot) then ~0.758 (R1).
Near-term pattern stats: modest upside odds next week (+1.58%) but essentially flat next month (-0.13%), not supportive of a strong buy-now thesis.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Earnings scheduled: 2026-02-16 (after hours) could act as an event-driven volatility catalyst.

Neutral/Negative Catalysts

- Primary trend remains bearish (SMA stack: 200 > 20 > 5).
- Price is currently under key support (S1 ~~0.583), increasing risk of a push toward S2 (~~0.528).
- No news flow in the past week: no fresh catalyst to justify chasing.
- Trading trends: Hedge funds and insiders are neutral—no supportive accumulation signal.
- Congress trading: no recent congress trading data available.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no YoY growth).
Profitability: Net income worsened to -2.15M (down -49.71% YoY).
EPS: -0.28 (down -67.06% YoY).
Overall: financial trajectory is deteriorating (bigger losses) with no revenue base, which weakens the buy case without a clear catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating / price target change data was provided, so there’s no observable recent Wall Street upgrade/downgrade trend.
Wall Street pro view (inferred from available data): potential upside relies on speculative catalysts; con view is the lack of revenue and worsening losses plus a bearish chart, making it unattractive for a buy-right-now decision.

Analyst Rating

Wall Street analysts forecast MTNB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTNB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold